Affinage

RARG

Retinoic acid receptor gamma · UniProt P13631

Length
454 aa
Mass
50.3 kDa
Annotated
2026-06-10
100 papers in source corpus 39 papers cited in narrative 39 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

RARγ is a ligand-activated nuclear receptor that, as a heterodimer with RXRα bound to retinoic acid response elements, transduces all-trans retinoic acid (RA) signals into transcriptional programs governing cellular differentiation, axial patterning, and stem cell fate (PMID:1320193, PMID:8524212, PMID:29848550). Atomic-resolution structures of its ligand-binding domain established the 'mouse trap' mechanism, in which RA binding repositions the C-terminal AF-2 helix-12 to seal the ligand pocket and create a transcriptionally active surface (PMID:7501014, PMID:9016769); integrity of this AF-2 helix is obligatory for RA-induced differentiation, and AF-2 deletions act as dominant negatives (PMID:10910773). Productive transactivation additionally requires p38MAPK phosphorylation of the AF-1 domain, which both releases the corepressor vinexin β and couples receptor turnover to activation through recruitment of the 19S proteasome subunit SUG-1 (PMID:12110588, PMID:12824162, PMID:15734736). RARγ controls a distinct subset of RA target genes (Hoxa-1, Cdx1, Stra6, Meis1, Cyp26a1) and the differentiation of embryonal carcinoma and embryonic stem cells, acting through epigenetic switching: in the unliganded state it nucleates an H2A.Z/Suz12 repressive configuration that is replaced by H3K9/K14 acetylation upon ligand-driven activation (PMID:7823950, PMID:7644503, PMID:20857416, PMID:23264745). In vivo it is the dominant RAR mediator of caudal axial patterning, restraining Wnt3a and Fgf8 to terminate axis elongation, and it maintains hematopoietic stem cell self-renewal and satellite-cell quiescence (PMID:12588859, PMID:24821986, PMID:16682494, PMID:36175396). Beyond the nucleus, RARγ functions as a cytoplasmic signaling scaffold: it is released from the nucleus to drive RIP1-dependent TNFR1 death-complex assembly, and it restrains inflammatory signaling by binding TRAF6 to block its oligomerization and NF-κB activation (PMID:28871172, PMID:38245869). A coding variant (p.Ser427Leu) reduces RARγ activity and derepresses TOP2B, impairing DNA repair and the cardioprotective ERK response to confer anthracycline-induced cardiotoxicity, which is reversed by genetic correction or RARγ agonists (PMID:26237429, PMID:34525346, PMID:32587261, PMID:35364012). RARG fusion proteins (NUP98-, CPSF6-, and tripartite X::RARG::Y) cause an atypical acute promyelocytic leukemia: consistent truncation of LBD helix 11-12 renders them ATRA-unresponsive, and they recruit HDAC3 to suppress myeloid differentiation genes such as PU.1 (PMID:25510432, PMID:39805830, PMID:39805831, PMID:39046762).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 1995 High

    Established how ligand binding switches the receptor on at the structural level, defining the activation mechanism for the whole RAR class.

    Evidence 2.0 Å crystal structure of the RA-bound RARγ LBD revealing the 'mouse trap' AF-2 helix repositioning

    PMID:7501014 PMID:9016769

    Open questions at the time
    • Structure of the full-length heterodimer on DNA not resolved
    • Does not capture corepressor- or coactivator-bound conformations
  2. 1992 High

    Showed RARγ acts on RAREs as an RXR heterodimer and is itself autoregulated, anchoring it in the RA transcriptional circuit.

    Evidence Reporter assays, RARE mutagenesis, and EMSA of the RARγ2 promoter

    PMID:1320193

    Open questions at the time
    • Sp1 cooperativity mechanism not detailed at the protein level
  3. 1995 High

    Defined RARγ as the principal RAR mediating differentiation and a specific subset of RA target genes, distinguishing it functionally from RARα/β.

    Evidence RARγ-null F9 cell knockout and isoform-specific rescue with target gene and differentiation readouts

    PMID:7644503 PMID:7823950 PMID:8524212

    Open questions at the time
    • Mechanistic basis for isoform target-gene selectivity not resolved
    • Partial redundancy with RARα leaves unique substrate set incompletely mapped
  4. 2000 High

    Pinned the differentiation function to the AF-2 helix-12 motif, linking structure to phenotype.

    Evidence AF-2 deletion mutants in RARγ-null F9 cells showing dominant-negative block of differentiation

    PMID:10910773

    Open questions at the time
    • Coactivators recruited via AF-2 in this context not identified
  5. 2002 High

    Connected receptor activation to phosphorylation and proteasomal turnover, showing transcription and degradation are coupled.

    Evidence p38MAPK and proteasome inhibition, SUG-1 Co-IP, AF-1/AF-2 mutagenesis, and pulse-chase in RARγ2

    PMID:12110588 PMID:12824162

    Open questions at the time
    • E3 ligase mediating ubiquitination not identified
    • Quantitative relationship between turnover rate and output undefined
  6. 2005 High

    Identified vinexin β as a phospho-regulated, RARγ-specific corepressor, explaining how AF-1 phosphorylation derepresses the receptor.

    Evidence Yeast two-hybrid, reciprocal Co-IP, colocalization, and gain/loss-of-function reporter assays

    PMID:15734736

    Open questions at the time
    • How vinexin β represses transcription mechanistically unclear
    • Genome-wide targets of this repression not mapped
  7. 2006 High

    Extended RARγ function to adult stem-cell biology, showing it maintains hematopoietic stem cell self-renewal.

    Evidence RARγ knockout mice, retroviral overexpression, and serial transplantation with selective agonists

    PMID:16682494

    Open questions at the time
    • Transcriptional targets governing self-renewal in HSCs not defined
    • Whether the same epigenetic switch operates in HSCs untested
  8. 2012 High

    Revealed RARγ's bimodal epigenetic mechanism: an unliganded H2A.Z/Suz12 repressive state that converts to an H3K9/K14ac active state upon RA.

    Evidence ChIP and Co-IP in RARγ-null ES cells across multiple chromatin marks and RA target loci

    PMID:20857416 PMID:23264745

    Open questions at the time
    • Enzymes depositing/removing H2A.Z and Suz12 in this context not identified
    • Locus-specific rules for chromatin requirement incompletely defined
  9. 2003 High

    Placed RARγ in vivo as the effector of caudal RA signaling controlling Wnt3a/Fgf8, with developmental epistasis to Cyp26a1.

    Evidence Cyp26a1/Rarg double-knockout rescue with in situ hybridization for Wnt3a/Fgf8

    PMID:11784046 PMID:12588859 PMID:24821986

    Open questions at the time
    • Direct vs. indirect regulation of Wnt3a/Fgf8 not separated
    • Corepressor identity sustaining the unliganded repressive state in vivo not defined
  10. 2017 High

    Revealed a non-genomic role: cytoplasmic RARγ scaffolds RIP1-initiated TNFR1 death complexes, expanding its function beyond transcription.

    Evidence shRNA screen, RARγ knockout, TNFR1-RIP1 Co-IP, subcellular fractionation, and in vivo necroptosis model

    PMID:28871172

    Open questions at the time
    • Signal that triggers nuclear export not defined
    • Direct binding interface with RIP1/TNFR1 not mapped
  11. 2015 High

    Linked an RARG coding variant to a human disease phenotype, defining a TOP2B-dependent mechanism of anthracycline cardiotoxicity.

    Evidence GWAS with functional reporter validation showing S427L derepresses TOP2B, replicated in three cohorts

    PMID:26237429

    Open questions at the time
    • How S427L alters receptor conformation/activity not resolved at this stage
  12. 2022 High

    Established causality and mechanism for S427L cardiotoxicity and demonstrated pharmacological rescue.

    Evidence CRISPR isogenic hiPSC-CMs, RNA-Seq, DNA damage/ROS assays, in vivo mouse model, and agonist rescue (CD1530)

    PMID:32587261 PMID:34525346 PMID:35364012

    Open questions at the time
    • Direct RARγ targets driving DNA repair impairment not fully enumerated
    • Clinical translatability of agonist rescue not established
  13. 2025 High

    Defined the molecular basis of RARG-fusion leukemia: helix 11-12 truncation produces ATRA-unresponsive receptors that recruit HDAC3 to block myeloid differentiation.

    Evidence Fusion characterization in patient cohorts, structural analysis, HDAC3 Co-IP, transformation assays, and HDAC inhibitor rescue in vivo

    PMID:25510432 PMID:39046762 PMID:39805830 PMID:39805831

    Open questions at the time
    • Allosteric mechanism of helix 11-12 truncation not structurally resolved
    • Full set of differentiation genes silenced by fusion-HDAC3 not mapped
  14. 2024 High

    Showed RARγ restrains tumor-associated inflammation by sequestering TRAF6, with lactylation-driven silencing releasing the brake.

    Evidence Reciprocal RARγ-TRAF6 Co-IP, TRAF6 ubiquitination assays, H3K18 lactylation ChIP, and in vivo CRC models

    PMID:38245869

    Open questions at the time
    • Whether TRAF6 sequestration is nuclear or cytoplasmic not pinned down
    • Generality beyond macrophages/CRC untested
  15. 2018 High

    Demonstrated RA transcriptional output is entirely RAR-dependent, formally bounding the receptor family's role.

    Evidence CRISPR triple knockout of all three RARs with genome-wide RNA-Seq in ES cells

    PMID:29848550

    Open questions at the time
    • Does not partition the RARγ-specific fraction of the transcriptome

Open questions

Synthesis pass · forward-looking unresolved questions
  • How RARγ partitions between its genomic (RARE/chromatin) and non-genomic (cytoplasmic scaffold) modes, and which signals govern its nuclear export, remains unresolved.
  • No structural model of cytoplasmic RARγ complexes
  • Trigger and machinery for nucleocytoplasmic shuttling undefined
  • Integration of phosphorylation, turnover, and localization into a unified switch unmapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 5 GO:0003677 DNA binding 3 GO:0008289 lipid binding 3 GO:0060089 molecular transducer activity 2 GO:0060090 molecular adaptor activity 2
Localization
GO:0005634 nucleus 4 GO:0000228 nuclear chromosome 2 GO:0005829 cytosol 2
Pathway
R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1266738 Developmental Biology 3 R-HSA-1643685 Disease 3 R-HSA-168256 Immune System 2 R-HSA-392499 Metabolism of proteins 2 R-HSA-4839726 Chromatin organization 2 R-HSA-5357801 Programmed Cell Death 2
Partners
CDK1HDAC3RIP1RXRASUG-1SUZ12TRAF6VINEXIN Β
Complex memberships
RARγ-RXRα heterodimerRARγ/Suz12 (PRC2-associated) complexTNFR1-RIP1 death complex (complex II/necrosome)

Evidence

Reading pass · 39 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1995 Crystal structure of the RARγ ligand-binding domain (LBD) bound to all-trans retinoic acid at 2.0 Å resolution reveals ligand-binding interactions and a 'mouse trap' mechanism: ligand binding induces a conformational transition that repositions the C-terminal amphipathic alpha-helix (AF-2 activating domain) to form a transcriptionally active receptor, sealing the ligand pocket. X-ray crystallography (2.0 Å resolution crystal structure) Nature High 7501014
1997 Purification of human RARγ LBD (residues 178–423) and determination that its Kd for all-trans retinoic acid is 0.6 ± 0.1 nM; crystals of the LBD–ligand complex were grown and confirmed to diffract to 2.0 Å. Recombinant protein purification (E. coli), ligand-binding assay, X-ray crystallography Biochemical and biophysical research communications High 9016769
2002 1.4 Å crystal structure of RARγ LBD complexed with retinoid SR11254 reveals multiple C-H…O hydrogen bonds between the ligand hydroxyl and the hydrophobic ligand pocket, providing a structural basis for receptor-subtype selectivity and affinity. X-ray crystallography (1.4 Å resolution) Structure High 12220491
1992 RARγ2 expression is autoregulated through a retinoic acid response element (RARE) in its own promoter, consisting of a 6-bp direct repeat with a 5-nucleotide spacer; this RARE is bound most effectively by RAR/RXR heterodimers, and Sp1 binding sites flanking the RARE synergistically enhance RARγ2 promoter activity. Reporter gene assays, cotransfection, mutational analysis of RARE, EMSA (receptor binding to RARE) Molecular and cellular biology High 1320193
1995 Targeted disruption of RARγ in F9 embryonal carcinoma cells specifically impairs RA-induced expression of Hoxa-1, Hoxa-3, laminin B1, collagen IV (α1), GATA-4, and BMP-2, and reduces metabolism of all-trans-RA to polar derivatives, demonstrating that RARγ regulates a distinct subset of RA target genes and RA metabolism. Homologous recombination knockout, RT-PCR/Northern blot for target gene expression, RA metabolism assay Molecular and cellular biology High 7823950
1995 RAR-RXR heterodimers require activation of both partners for synergistic induction of RA-responsive endogenous genes and differentiation of P19 and F9 cells; RARγ-selective retinoids combined with RXR-selective retinoids synergistically induce differentiation, demonstrating functional redundancy between RARα, RARβ, and RARγ in this context. Selective synthetic retinoids in cell-based differentiation assays, gene expression analysis Molecular and cellular biology High 8524212
1995 Reexpression of RARγ2 in RARγ-null F9 cells restores both RA-target gene activation (Cdx1, Gap43, Stra4, Stra6) and differentiation potential; overexpression of RARα can partially substitute, but RARβ overexpression only poorly restores differentiation, establishing partial functional redundancy between RAR subtypes with RARγ as the primary mediator of differentiation. Stable rescue cell lines, RT-PCR for target gene expression, morphological differentiation assay Proceedings of the National Academy of Sciences of the United States of America High 7644503
1997 Phosphorylation of both AF-1 and AF-2 activation functions of RARγ2 is required for RA-induced primitive endodermal differentiation of F9 cells; AF-1 phosphorylation at the proline-directed kinase site of RARγ2 is specifically required for primitive endoderm, while parietal differentiation additionally requires RARα1 AF-1 phosphorylation and PKA-site phosphorylation of RARα AF-2. Phosphorylation site mutagenesis, stable cell lines in RARγ-null F9 cells, differentiation assays The EMBO journal High 9351827
2002 Upon RA binding, RARγ2 undergoes proteasome-dependent degradation signaled through both AF-1 (phosphorylated by p38MAPK) and AF-2 (via recruitment of SUG-1, a component of the 19S regulatory subunit of the 26S proteasome); blocking either p38MAPK or proteasome function impairs RARγ2 transactivation activity, linking receptor turnover to transcriptional activation. Pharmacological inhibition of p38MAPK and proteasome, co-immunoprecipitation of SUG-1, mutagenesis of AF-1/AF-2, reporter gene assays, pulse-chase degradation assay The EMBO journal High 12110588
2003 RARγ2 is the 'engine' of the RAR heterodimer driving both transcription and its own proteasomal degradation after ligand binding; integrity of its AF-2 domain and phosphorylation of its AF-1 domain are required for both degradation and transactivation; RXRα plays a modulatory/cooperative role through its own AF-1 (phosphorylated) and AF-2 domains. Domain deletion mutants, AF-1 phosphorylation site mutants, transfection assays, ubiquitin-proteasome pathway analysis The Journal of biological chemistry High 12824162
2005 Vinexin β, a SH3 motif-containing cytoskeletal protein, interacts with the non-phosphorylated AF-1 domain of RARγ (but not RARα or RARβ); upon phosphorylation of AF-1, vinexin β dissociates. Vinexin β colocalizes with RARγ in the nucleus and functions as a repressor of RARγ-mediated transcription, as demonstrated by overexpression and RNAi knockdown. Yeast two-hybrid, co-immunoprecipitation, immunofluorescence colocalization, stable overexpression, siRNA knockdown, reporter assays The Journal of biological chemistry High 15734736
2015 A nonsynonymous coding variant in RARG (rs2229774, p.Ser427Leu) is associated with anthracycline-induced cardiotoxicity; this variant alters RARG function, leading to derepression of TOP2B (topoisomerase 2β), which is a key genetic determinant of anthracycline-induced cardiotoxicity. GWAS with functional validation: reporter/expression assays showing derepression of TOP2B by RARG S427L variant Nature genetics High 26237429
2021 The RARG S427L variant (rs2229774) mediates increased doxorubicin-induced cardiotoxicity by suppressing TOP2B expression and failing to activate the cardioprotective ERK pathway; the RARγ agonist CD1530 attenuates doxorubicin-induced cardiotoxicity in patient-specific hiPSC-CMs and in vivo mouse models. Patient-specific hiPSC-CMs, CRISPR isogenic lines, molecular pathway analysis (ERK, TOP2B), in vivo mouse DIC model, pharmacological rescue Cell stem cell High 34525346
2020 CRISPR/Cas9 correction of RARG-S427L to wild type reduces doxorubicin-induced double-stranded DNA breaks, ROS production, and cell death in iPSC-CMs; introduction of S427L increases susceptibility; genetic disruption of RARG protects from doxorubicin-induced cell death, establishing a direct causal role for RARG S427L in DIC. CRISPR/Cas9 isogenic iPSC-CM lines, cell viability, optical mapping, DNA damage (γH2AX), ROS assays Scientific reports High 32587261
2022 RARG p.S427L variant leads to reduced activation of RARG target genes (including DNA repair pathways) in response to doxorubicin in iPSC-CMs, resulting in impaired DNA repair; molecular dynamic simulations predict structural changes confirmed by gene expression studies. Molecular dynamic simulations, CRISPR-edited iPSC-CMs, RNA-Seq, DNA damage assays Stem cell reports High 35364012
2022 ATRA activates RARγ, induces interferon-β response and IRF1 expression; IRF1 initiates transcription of OAS1, which synthesizes 2-5A to activate RNase L and cause RNA degradation and cell death, thereby sensitizing multiple myeloma cells to carfilzomib; selective RARγ agonist BMS961 recapitulates this effect. High-throughput drug screen, selective RARγ agonist, gene knockdown, reporter assays, in vivo myeloma model Blood Medium 34411225
2006 RARγ is selectively expressed in primitive hematopoietic precursors; RARγ knockout mice show markedly reduced HSC numbers with increased mature progenitors; overexpression of RARγ (but not RARα) in primitive precursors maintains an undifferentiated phenotype; pharmacological RARγ activation promotes HSC self-renewal as shown by serial transplant studies. RARγ knockout mice, competitive transplantation, retroviral overexpression, ex vivo culture with selective agonists, serial transplant The Journal of experimental medicine High 16682494
2011 In embryonic stem cells, RARγ (in the absence of ligand RA) is required for deposition of the histone variant H2A.Z and polycomb group protein Suz12 at RA target gene loci; RARγ and Suz12 exist in a multi-protein complex in the absence of ligand. Upon RA addition, H2A.Z and Suz12 are removed from these loci concurrent with transcriptional activation. ChIP, co-immunoprecipitation, RARγ-null ES cells Journal of cellular physiology Medium 20857416
2012 RARγ is required for RA-induced chromatin remodeling (H3K9/K14ac increase at proximal promoters) and transcriptional activation of a subset of RA target genes (e.g., Meis1, Lrat, Stra6, Crabp2, Cyp26a1) in embryonic stem cells; H3K4me3 at Meis1 proximal promoter does not require RARγ, revealing gene-specific epigenetic requirements. RARγ knockout ES cells, RNA-Seq/RT-PCR, ChIP for H3K9/K14ac and H3K4me3 Journal of cell science High 23264745
2003 In Cyp26a1-null mice, ectopic RA signaling in the tail bud is mediated specifically by RARγ; activated RARγ downregulates Wnt3a and Fgf8. Genetic ablation of Rarg rescues Cyp26a1-null mice from caudal regression and embryonic lethality, demonstrating that CYP26A1 suppresses RARγ-mediated downregulation of WNT3A and FGF8 signaling pathways. Compound Cyp26a1/Rarg double knockout mice, in situ hybridization for Wnt3a and Fgf8, embryo survival analysis Development High 12588859
2009 TNIP1 acts as an atypical corepressor of agonist-bound RARα and RARγ: it requires NR boxes, ligand, and the receptor's AF-2 domain for interaction (properties characteristic of coactivators), yet represses RAR activity; repression is partially relieved by SRC1; preferential interaction of RARα over RARγ maps to helices 5–9 of the RARα LBD. Co-immunoprecipitation, deletion/domain mutants, reporter gene assays, competitive binding with SRC1 Biochemical and biophysical research communications Medium 19732752
2017 Cytoplasmic RARγ controls RIP1-initiated apoptosis and necroptosis when cIAP activity is blocked downstream of TNF receptor 1; RARγ mediates RIP1 dissociation from TNFR1, initiating cytosolic death complex (complex II/necrosome) formation. In response to cIAP inhibition, RARγ is released from the nucleus to orchestrate formation of cytosolic death complexes. shRNA library screen, RARγ knockdown/knockout, co-immunoprecipitation of TNFR1-RIP1 complex, subcellular fractionation, in vivo TNF-induced necroptosis model Nature communications High 28871172
2014 RARγ2 is engaged in active transcriptional repression (via co-repressor complex) throughout axial elongation in Xenopus, not only as a terminator; in the absence of RA, unliganded RARγ2 represses caudal progenitor genes to maintain the progenitor pool; upon RA, RARγ2 switches to activator, facilitating somite differentiation. Dominant-negative co-repressor or VP16-RARγ2 overexpression prematurely terminates axis elongation. Dominant-negative RARγ overexpression, selective RARγ inverse agonist (NRX205099) and agonist (NRX204647), dominant-negative co-repressor (c-SMRT), Xenopus embryo in vivo assays, in situ hybridization Development High 24821986
2014 NUP98-RARG fusion protein acquires nuclear localization patterns and transcriptional properties similar to RARA fusions; its oncogenic transformation of hematopoietic stem/progenitor cells depends on the C-terminal GLFG domain of NUP98 and the DNA-binding domain of RARG; NUP98-RARG homodimerizes and recruits both RXRA and wild-type NUP98; transformed cells are sensitive to ATRA. Murine bone marrow retroviral transduction/transformation assay, domain deletion mutants, nuclear localization imaging, reporter gene assays, Co-IP Leukemia High 25510432
2016 RARγ promotes phosphorylation of Lats1 and Yap binding to Lats1, thereby inactivating Yap target gene expression and suppressing colorectal cancer; knockdown of RARγ activates Hippo-Yap oncogenic signaling, driving cancer cell growth, invasion, and metastasis. RARγ knockdown, Co-IP of Lats1-Yap, phosphorylation assays, in vitro invasion assays, in vivo xenograft Cancer research Medium 27325643
2024 In macrophages, RARγ interacts with TRAF6 and prevents TRAF6 oligomerization and autoubiquitination, thereby inhibiting NF-κB signaling; tumor-derived lactate drives H3K18 lactylation to suppress RARγ gene transcription, releasing TRAF6 to promote IL-6/STAT3 signaling. NDGA directly binds RARγ to inhibit TRAF6-IL-6-STAT3 axis. Co-immunoprecipitation of RARγ-TRAF6, chromatin modification analysis (H3K18 lactylation ChIP), TRAF6 ubiquitination assays, direct binding assay (NDGA-RARγ), in vivo colorectal cancer models Cell reports High 38245869
2025 CPSF6-RARG fusion (CR) interacts with HDAC3 to suppress expression of myeloid differentiation genes including PU.1; disrupting the CR-HDAC3 interaction restores PU.1 expression and myeloid differentiation; HDAC inhibitors suppress CR-driven leukemia in vitro and in vivo. Co-immunoprecipitation of CR-HDAC3, gene expression analysis, HDAC inhibitor treatment, in vivo leukemia model Nature communications High 39805830
2025 RARG fusions disrupt myeloid differentiation and promote HSPC proliferation/self-renewal by upregulating BCL2 and ATF3; co-occurrence with heterozygous Wt1 loss induces fully penetrant AML by activating MYC and HOXA9/MEIS1 targets; all RARG-aAPL cases harbor tripartite X::RARG::X fusions with truncation of LBD helix 11–12, which is mechanistically responsible for ATRA unresponsiveness through protein allosteric dysfunction. Retroviral transduction/transformation assays, RNA-Seq, molecular structure analysis, high-throughput drug screening (Connectivity Map) Nature communications High 39805831
2024 All RARG-aAPL cases harbor tripartite X::RARG::Y fusion transcripts with RARG 3' splice consistently at the terminus of exon 9, resulting in LBD helix 11–12 truncation; this truncation (not present in artificially mimicked bipartite fusions) drives ATRA unresponsiveness and leukemogenesis through protein allosteric dysfunction. Molecular investigation of fusion transcripts in 21 RARG-aAPL cases, protein structural analysis, experimental functional assays Blood High 39046762
2013 CDK1 interacts with RARγ in the nucleus; RARγ regulates CDK1 protein levels and its subcellular localization in response to ATRA; CDK1 is required for optimal ATRA effect in U-937 leukemic cells and modulates P27(kip) and AKT phosphorylation; CDK1 and RARγ form a reciprocal regulatory circuit influencing each other's protein stability. Co-immunoprecipitation, subcellular fractionation, CDK1 inhibition, immunofluorescence, Western blot in leukemia cells Cell cycle Medium 23518499
2014 In ATRA-inhibited adipocyte differentiation, RARγ (but not RARα) interacts with C-Fos protein; this interaction inhibits C-Fos DNA binding activity at the PPARγ2 promoter, reducing PPARγ2 expression and blocking adipocyte differentiation; RARγ inhibitor blocks ATRA-induced reduction of C-Fos binding to PPARγ2 promoter. Co-immunoprecipitation of RARγ-C-Fos, chromatin immunoprecipitation (ChIP) for C-Fos at PPARγ2 promoter, RARγ inhibitor, Western blot Biochimie Medium 25173565
2022 RARγ binds to and stimulates genes responsible for Akt dephosphorylation in satellite cells, inhibiting overall protein translation initiation to maintain quiescence; alleviation of retinoic acid signaling releases satellite cells from quiescence; this restraint is lost in aged cells. ChIP for RARγ occupancy at target genes, in vivo satellite cell activation assays, RA signaling inhibition, aged vs. young muscle comparison Cell death & disease Medium 36175396
2018 miR-96 directly targets RARγ mRNA to downregulate RARγ expression; reduced RARγ levels (independent of exogenous retinoid) impact prostate cell viability; RARγ cistrome is enriched at active enhancers associated with AR binding sites, and RARγ knockdown significantly alters the magnitude of the AR transcriptome. miR-96 mimic/biotin-miR-96 targetome capture, luciferase 3'UTR reporter assay, ChIP-Seq (RARγ cistrome), shRNA knockdown, RNA-Seq Oncogene Medium 30120411
2022 A synthetic retinoid induces RARγ translocation from the nucleus to the cytoplasm; nuclear RARγ normally binds the Cdc42 promoter; cytoplasmic translocation reduces RARγ-Cdc42 promoter binding, downregulating Cdc42, decreasing F-actin, and inhibiting cytoskeletal tension, leading to chromatin decondensation and DNA damage in tumor-repopulating cells. Immunofluorescence/live imaging for RARγ translocation, ChIP for RARγ at Cdc42 promoter, Cdc42/F-actin rescue experiments, tumor-repopulating cell apoptosis assay Advanced science Medium 36031407
2004 Ligation of RARγ (but not RARα) by selective agonists inhibits proliferation of PHA-stimulated T cells by preventing IL-2-induced upregulation of JAK3 protein levels (without affecting JAK1), thereby inhibiting STAT5 phosphorylation and Rb phosphorylation. Selective RARγ agonists, RARγ antagonist, Western blot for JAK1/JAK3/STAT5/Rb, T cell proliferation assay Immunology letters Medium 15790515
2004 In IP-12-7 T cells, RA induces nur77 expression and DNA binding, and FasL cell surface appearance via RARγ; two RARγ-selective compounds (CD437 and CD2325) initiate apoptosis while natural RA cannot, because natural RA-liganded RARγ cannot sensitize the Fas death pathway even though it induces FasL expression. Selective RAR agonists/antagonists, EMSA for nur77 DNA binding, flow cytometry for FasL surface expression, apoptosis assays European journal of immunology Medium 14991612
2001 RARγ and Cdx1 interact synergistically in vertebral patterning: compound RARγ-Cdx1 double null mutants show increased severity of cervical homeotic transformations relative to single nulls; exogenous RA requires Cdx1 for full vertebral morphogenetic effects, placing RARγ upstream of Cdx1 in axial patterning while also indicating parallel pathways converging on common targets. Compound null mouse genetics, skeletal phenotype analysis, RA treatment of compound nulls Developmental biology High 11784046
2000 The conserved amphipathic alpha-helical core motif (helix 12) of RARγ AF-2 is required for RA-induced differentiation of F9 cells and RA target gene expression; AF-2 deletion mutants of RARγ2 and RARα1 behave as dominant negatives, blocking differentiation. Stable cell lines expressing AF-2 deletion mutants in RARγ-null F9 cells, differentiation assays, target gene expression analysis Journal of cell science High 10910773
2018 Combinatorial knockout of all three RAR isoforms (RARα, RARβ, RARγ) by CRISPR completely abrogates all transcriptional responses to RA in murine embryonic stem cells, demonstrating that the transcriptional effects of RA are entirely RAR-dependent with no RAR-independent transcriptional route. CRISPR biallelic knockout of all three RARs, RNA-Seq transcriptome analysis The Journal of biological chemistry High 29848550

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1995 Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 965 7501014
2015 A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nature genetics 222 26237429
2006 RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. The Journal of experimental medicine 168 16682494
1995 Targeted disruption of retinoic acid receptor alpha (RAR alpha) and RAR gamma results in receptor-specific alterations in retinoic acid-mediated differentiation and retinoic acid metabolism. Molecular and cellular biology 152 7823950
1995 Synergistic activation of retinoic acid (RA)-responsive genes and induction of embryonal carcinoma cell differentiation by an RA receptor alpha (RAR alpha)-, RAR beta-, or RAR gamma-selective ligand in combination with a retinoid X receptor-specific ligand. Molecular and cellular biology 141 8524212
2002 Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma degradation and transactivation. The EMBO journal 126 12110588
2002 Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-gamma and altered expression of Bcl-2/Bax. British journal of cancer 119 12189556
2024 Histone lactylation inhibits RARγ expression in macrophages to promote colorectal tumorigenesis through activation of TRAF6-IL-6-STAT3 signaling. Cell reports 116 38245869
1992 RAR gamma 2 expression is regulated through a retinoic acid response element embedded in Sp1 sites. Molecular and cellular biology 115 1320193
1997 Phosphorylation of activation functions AF-1 and AF-2 of RAR alpha and RAR gamma is indispensable for differentiation of F9 cells upon retinoic acid and cAMP treatment. The EMBO journal 99 9351827
1995 Reexpression of retinoic acid receptor (RAR) gamma or overexpression of RAR alpha or RAR beta in RAR gamma-null F9 cells reveals a partial functional redundancy between the three RAR types. Proceedings of the National Academy of Sciences of the United States of America 99 7644503
2015 Attenuation of EMT in RPE cells and subretinal fibrosis by an RAR-γ agonist. Journal of molecular medicine (Berlin, Germany) 71 25947075
2010 A novel NUP98/RARG gene fusion in acute myeloid leukemia resembling acute promyelocytic leukemia. Blood 66 20935257
2003 Developing with lethal RA levels: genetic ablation of Rarg can restore the viability of mice lacking Cyp26a1. Development (Cambridge, England) 66 12588859
2021 RARG variant predictive of doxorubicin-induced cardiotoxicity identifies a cardioprotective therapy. Cell stem cell 65 34525346
2002 C-H...O hydrogen bonds in the nuclear receptor RARgamma--a potential tool for drug selectivity. Structure (London, England : 1993) 62 12220491
1997 Specific activation of retinoic acid receptors (RARs) and retinoid X receptors reveals a unique role for RARgamma in induction of differentiation and apoptosis of S91 melanoma cells. The Journal of biological chemistry 62 9228081
2012 RARγ is essential for retinoic acid induced chromatin remodeling and transcriptional activation in embryonic stem cells. Journal of cell science 60 23264745
2016 RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway. Cancer research 56 27325643
2006 Characterization of the retinoic acid receptor genes raraa, rarab and rarg during zebrafish development. Gene expression patterns : GEP 54 16455309
1995 Genesis and prevention of spinal neural tube defects in the curly tail mutant mouse: involvement of retinoic acid and its nuclear receptors RAR-beta and RAR-gamma. Development (Cambridge, England) 50 7720576
2018 The miR-96 and RARγ signaling axis governs androgen signaling and prostate cancer progression. Oncogene 48 30120411
2005 Vinexin beta interacts with the non-phosphorylated AF-1 domain of retinoid receptor gamma (RARgamma) and represses RARgamma-mediated transcription. The Journal of biological chemistry 45 15734736
1999 4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARgamma independent pathway. Oncogene 44 10523855
2017 Activation of RARα, RARγ, or RXRα Increases Barrier Tightness in Human Induced Pluripotent Stem Cell-Derived Brain Endothelial Cells. Biotechnology journal 40 28960887
2003 The AF-1 and AF-2 domains of RAR gamma 2 and RXR alpha cooperate for triggering the transactivation and the degradation of RAR gamma 2/RXR alpha heterodimers. The Journal of biological chemistry 40 12824162
2001 RARgamma and Cdx1 interactions in vertebral patterning. Developmental biology 39 11784046
2012 MIR-34c regulates mouse embryonic stem cells differentiation into male germ-like cells through RARg. Cell biochemistry and function 38 23097316
2014 Critical role of retinoid/rexinoid signaling in mediating transformation and therapeutic response of NUP98-RARG leukemia. Leukemia 37 25510432
2004 RARgamma acts as a tumor suppressor in mouse keratinocytes. Oncogene 37 15094780
1995 Marked resistance of RAR gamma-deficient mice to the toxic effects of retinoic acid. The American journal of physiology 37 7631783
2017 The cytoplasmic nuclear receptor RARγ controls RIP1 initiated cell death when cIAP activity is inhibited. Nature communications 36 28871172
2002 The retinoic acid receptors RARalpha and RARgamma are required for inner ear development. Mechanisms of development 35 12464434
2020 Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes. Scientific reports 34 32587261
2014 Active repression by RARγ signaling is required for vertebrate axial elongation. Development (Cambridge, England) 34 24821986
2012 Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis. Breast cancer research : BCR 34 22920668
1996 Pattern of retinoid-induced teratogenic effects: possible relationship with relative selectivity for nuclear retinoid receptors RAR alpha, RAR beta, and RAR gamma. Teratology 34 8761883
1999 Synthesis, structure-activity relationships, and RARgamma-ligand interactions of nitrogen heteroarotinoids. Journal of medicinal chemistry 33 10479291
1993 The pattern of retinoic acid receptor gamma (RAR gamma) expression in normal development of Xenopus laevis and after manipulation of the main body axis. Mechanisms of development 33 8389582
2016 RARγ-induced E-cadherin downregulation promotes hepatocellular carcinoma invasion and metastasis. Journal of experimental & clinical cancer research : CR 31 27756432
2013 CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemia. Cell cycle (Georgetown, Tex.) 31 23518499
1997 Limited specificity and large overlap of the functions of the mouse RAR gamma 1 and RAR gamma 2 isoforms. Mechanisms of development 31 9376317
2018 A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion. Blood advances 30 29891591
1994 Regional specificity of RAR gamma isoforms in Xenopus development. Mechanisms of development 30 8199051
2019 A novel NPM1-RARG-NPM1 chimeric fusion in acute myeloid leukaemia resembling acute promyelocytic leukaemia but resistant to all-trans retinoic acid and arsenic trioxide. British journal of cancer 28 30996344
1997 Downregulation of RAR alpha in mice by antisense transgene leads to a compensatory increase in RAR beta and RAR gamma and development of lymphoma. Blood 28 9116296
2010 Analysis of Cyp26b1/Rarg compound-null mice reveals two genetically separable effects of retinoic acid on limb outgrowth. Developmental biology 26 20043900
2009 Retinoid receptor subtype-selective modulators through synthetic modifications of RARgamma agonists. Bioorganic & medicinal chemistry 26 19482478
2015 RARγ is a negative regulator of osteoclastogenesis. The Journal of steroid biochemistry and molecular biology 25 25800721
2014 RARγ-C-Fos-PPARγ2 signaling rather than ROS generation is critical for all-trans retinoic acid-inhibited adipocyte differentiation. Biochimie 25 25173565
2001 Increased retinoic acid responsiveness in lung carcinoma cells that are nonresponsive despite the presence of endogenous retinoic acid receptor (RAR) beta by expression of exogenous retinoid receptors retinoid X receptor alpha, RAR alpha, and RAR gamma. Cancer research 25 11212249
2023 A global study for acute myeloid leukemia with RARG rearrangement. Blood advances 23 36799929
2009 Liganded RARalpha and RARgamma interact with but are repressed by TNIP1. Biochemical and biophysical research communications 23 19732752
2018 RARA and RARG gene downregulation associated with EZH2 mutation in acute promyelocytic-like morphology leukemia. Human pathology 22 29530751
2011 RARγ is required for correct deposition and removal of Suz12 and H2A.Z in embryonic stem cells. Journal of cellular physiology 22 20857416
2020 Clinical Pharmacology and Safety of Trifarotene, a First-in-Class RARγ-Selective Topical Retinoid. Journal of clinical pharmacology 21 32017149
2020 Acute Myeloid Leukemia with NUP98-RARG Gene Fusion Similar to Acute Promyelocytic Leukemia: Case Report and Literature Review. OncoTargets and therapy 21 33116634
2003 Function of RARgamma and RARalpha2 at the initiation of retinoid signaling is essential for avian embryo survival and for distinct events in cardiac morphogenesis. Developmental dynamics : an official publication of the American Association of Anatomists 21 14648846
2019 RARG Gene Dysregulation in Acute Myeloid Leukemia. Frontiers in molecular biosciences 20 31709264
2022 RARγ activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood 19 34411225
2016 Identification of potent and selective retinoic acid receptor gamma (RARγ) antagonists for the treatment of osteoarthritis pain using structure based drug design. Bioorganic & medicinal chemistry letters 19 27261179
2022 RARG S427L attenuates the DNA repair response to doxorubicin in induced pluripotent stem cell-derived cardiomyocytes. Stem cell reports 18 35364012
2021 The RARγ Oncogene: An Achilles Heel for Some Cancers. International journal of molecular sciences 18 33807298
2020 Alkaloid-based regimen is beneficial for acute myeloid leukemia resembling acute promyelocytic leukemia with NUP98/RARG fusion and RUNX1 mutation: A case report. Medicine 18 33019444
2018 Combinatorial knockout of RARα, RARβ, and RARγ completely abrogates transcriptional responses to retinoic acid in murine embryonic stem cells. The Journal of biological chemistry 18 29848550
2014 Retinoic acid receptor γ (Rarg) and nuclear receptor subfamily 5, group A, member 2 (Nr5a2) promote conversion of fibroblasts to functional neurons. The Journal of biological chemistry 18 24459144
2022 Retinoic acid and RARγ maintain satellite cell quiescence through regulation of translation initiation. Cell death & disease 17 36175396
2015 TSLP expression in the skin is mediated via RARγ-RXR pathways. Immunobiology 16 26531761
2001 Synergistic teratogenic effects induced by retinoids in mice by coadministration of a RARalpha- or RARgamma-selective agonist with a RXR-selective agonist. Toxicology and applied pharmacology 16 11141350
2022 Synthetic Retinoid Kills Drug-Resistant Cancer Stem Cells via Inducing RARγ-Translocation-Mediated Tension Reduction and Chromatin Decondensation. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 14 36031407
2021 Acute myeloid leukemia with CPSF6-RARG fusion resembling acute promyelocytic leukemia with extramedullary infiltration. Therapeutic advances in hematology 14 33473264
2020 Temporal activation of LRH-1 and RAR-γ in human pluripotent stem cells induces a functional naïve-like state. EMBO reports 14 33252195
2008 Regulation of CD8(+) T cell functions by RARgamma. Seminars in immunology 14 18715802
2000 RAR gamma agonists inhibit proliferation of vascular smooth muscle cells. Journal of cardiovascular pharmacology 14 10672865
2022 A non-retinol retinoic acid receptor-γ (RAR-γ/NR1B3) selective agonist, tectorigenin, can effectively inhibit the ultraviolet A-induced skin damage. British journal of pharmacology 13 35731978
2022 High expression of RARG accelerates ovarian cancer progression by regulating cell proliferation. Frontiers in oncology 13 36523991
2005 Comedolytic effect of a novel RARgamma-specific retinoid, ER36009: comparison with retinoic acid in the rhino mouse model. European journal of dermatology : EJD 13 16280299
1999 The RARgamma selective agonist CD437 inhibits gastric cell growth through the mechanism of apoptosis. Cancer letters 13 10374844
1997 Purification of the human RARgamma ligand-binding domain and crystallization of its complex with all-trans retinoic acid. Biochemical and biophysical research communications 13 9016769
2024 Critical role of tripartite fusion and LBD truncation in certain RARA- and all RARG-related atypical APL. Blood 12 39046762
2023 Case report: Identification of a novel HNRNPC::RARG fusion in acute promyelocytic leukemia lacking RARA rearrangement. Frontiers in oncology 12 36713535
2023 Blockage of retinoic acid signaling via RARγ suppressed the proliferation of pancreatic cancer cells by arresting the cell cycle progression of the G1-S phase. Cancer cell international 12 37198667
2022 A short report of novel RARG-HNRNPM fusion gene in resembling acute promyelocytic leukemia. Hematology (Amsterdam, Netherlands) 12 35544458
2022 All-trans retinoic acid (ATRA) regulates key genes in the RARG-TOP2B pathway and reduces anthracycline-induced cardiotoxicity. PloS one 12 36331922
2020 Understanding the Action of RARγ Agonists on Human Osteochondroma Explants. International journal of molecular sciences 12 32294904
2019 Postoperative cognitive dysfunction after robot-assisted radical cystectomy (RARC) with cerebral oxygen monitoring an observational prospective cohort pilot study. BMC anesthesiology 12 31694553
1992 Retinoic acid receptor isoform RAR gamma 1: an antagonist of the transactivation of the RAR beta RARE in epithelial cell lines and normal human keratinocytes. Molecular biology reports 12 1337576
2020 Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report. BMC musculoskeletal disorders 11 32245464
2022 Antagonizing RARγ Drives Necroptosis of Cancer Stem Cells. International journal of molecular sciences 10 35563205
2000 The conserved amphipatic alpha-helical core motif of RARgamma and RARalpha activating domains is indispensable for RA-induced differentiation of F9 cells. Journal of cell science 10 10910773
1999 Hoxd4 and Rarg interact synergistically in the specification of the cervical vertebrae. Mechanisms of development 10 10559481
2017 RARα and RARγ reciprocally control K5+ progenitor cell expansion in developing salivary glands. Organogenesis 9 28933645
2014 BCL-xL/MCL-1 inhibition and RARγ antagonism work cooperatively in human HL60 leukemia cells. Experimental cell research 9 25088254
2004 Ligation of RARgamma inhibits proliferation of phytohaemagglutinin-stimulated T-cells via down-regulating JAK3 protein levels. Immunology letters 9 15790515
2023 RARγ promotes the invasion and metastasis of thyroid carcinoma by activating the JAK1-STAT3-CD24/MMPs axis. International immunopharmacology 8 37897947
2022 A Novel NUP98/RARG Gene Fusion in Pediatric Acute Myeloid Leukemia Resembling Acute Promyelocytic Leukemia. Journal of pediatric hematology/oncology 8 35319505
2006 Topical ER36009, a RARgamma-selective retinoid, decreases abdominal white adipose tissue and elicits changes in expression of genes related to adiposity and thermogenesis. Endocrine 8 17185799
2004 Retinoids induce Fas(CD95) ligand cell surface expression via RARgamma and nur77 in T cells. European journal of immunology 8 14991612
2025 CPSF6-RARγ interacts with histone deacetylase 3 to promote myeloid transformation in RARG-fusion acute myeloid leukemia. Nature communications 7 39805830
2025 Oncogenic role of RARG rearrangements in acute myeloid leukemia resembling acute promyelocytic leukemia. Nature communications 7 39805831

Missed literature

Know a paper Affinage missed for RARG? Flag it for the maintainers and the community.

No submissions yet.